Literature DB >> 19103616

Treatment of idiopathic chylothorax in 14 dogs by ligation of the thoracic duct and partial pericardiectomy.

B Carobbi1, R A S White, G Romanelli.   

Abstract

The outcome and complications associated with thoracic duct ligation combined with partial pericardiectomy in 14 dogs with idiopathic chylothorax were investigated retrospectively. Nine of the dogs were treated in the uk and five in Italy. All of them were reassessed clinically four weeks after surgery and the respiratory function and any pleural fluid accumulation were evaluated; they were followed up by telephone contact for at least six months. Eleven of the dogs were clinically normal and had no radiographic signs of pleural effusion when reassessed after four weeks. Two showed radiographic signs of a minor accumulation of pleural fluid but were clinically normal; when reassessed after three months they showed similar radiographic signs and clinical findings; but after four months there was no evidence of pleural effusion. One dog had a major complication that required a second surgical intervention.

Entities:  

Mesh:

Year:  2008        PMID: 19103616

Source DB:  PubMed          Journal:  Vet Rec        ISSN: 0042-4900            Impact factor:   2.695


  3 in total

1.  Thoracic duct lymphography by subcutaneous contrast agent injection in a dog with chylothorax.

Authors:  T Iwanaga; S Tokunaga; Y Momoi
Journal:  Open Vet J       Date:  2016-12-08

2.  Triple-combination surgery with thoracic duct ligation, partial pericardiectomy, and cisterna chyli ablation for treatment of canine idiopathic chylothorax.

Authors:  Kumiko Ishigaki; Takahiro Nagumo; Naoki Sakurai; Kazushi Asano
Journal:  J Vet Med Sci       Date:  2022-06-08       Impact factor: 1.105

3.  Prevalence, outcome and risk factors for postoperative pyothorax in 232 dogs undergoing thoracic surgery.

Authors:  L B Meakin; L K Salonen; S J Baines; D J Brockman; S P Gregory; Z J Halfacree; V J Lipscomb; K C Lee
Journal:  J Small Anim Pract       Date:  2013-04-15       Impact factor: 1.522

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.